Header Logo

YIXIN YAO

TitleInstructor
InstitutionMD Anderson
DepartmentMolecular & Cellular Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Li Y, Lee HH, Jiang VC, Che Y, McIntosh J, Jordan A, Vargas J, Zhang T, Yan F, Simmons ME, Wang W, Nie L, Yao Y, Jain P, Wang M, Liu Y. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death Dis. 2023 11 02; 14(11):714. PMID: 37919300; PMCID: PMC10622549.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Che Y, Liu Y, Li Y, McIntosh JM, Jordan A, Yan F, Wang W, Nie L, Lee HH, Jin J, Yao Y, Zhao Z, Jiang VC, Wang M. Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Adv. 2023 07 25; 7(14):3361-3365. PMID: 37257192; PMCID: PMC10345850.
      Citations:    Fields:    Translation:Humans
    3. Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, Che Y, Vargas J, Chen Z, Leeming A, Wang W, Yao Y, Wang M, Jiang VC. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 06 01; 108(6):1616-1627. PMID: 36420799; PMCID: PMC10230437.
      Citations: 4     Fields:    Translation:HumansCells
    4. Liu Y, Yan F, Jiang VC, Li Y, Che Y, McIntosh J, Jordan A, Hou I, Nie L, Jin J, Wang W, Lee HH, Yao Y, Wang M. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma. Haematologica. 2023 05 01; 108(5):1412-1416. PMID: 36475521; PMCID: PMC10153528.
      Citations:    Fields:    Translation:Humans
    5. Che Y, Liu Y, Yao Y, Hill HA, Li Y, Cai Q, Yan F, Jain P, Wang W, Rui L, Wang M. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023 02 17; 13(1):27. PMID: 36797243; PMCID: PMC9935633.
      Citations: 4     Fields:    Translation:Animals
    6. Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022 09 26; 21(1):185. PMID: 36163179; PMCID: PMC9513944.
      Citations: 7     Fields:    Translation:HumansCells
    7. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415. PMID: 35074072.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Park MK, Zhang L, Min KW, Cho JH, Yeh CC, Moon H, Hormaechea-Agulla D, Mun H, Ko S, Lee JW, Jathar S, Smith AS, Yao Y, Giang NT, Vu HH, Yan VC, Bridges MC, Kourtidis A, Muller F, Chang JH, Song SJ, Nakagawa S, Hirose T, Yoon JH, Song MS. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab. 2021 12 07; 33(12):2380-2397.e9. PMID: 34879239; PMCID: PMC8813003.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    9. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212. PMID: 34797699; PMCID: PMC8718245.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    10. Jung D, Jain P, Yao Y, Wang M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol. 2020 09 24; 13(1):127. PMID: 32972438; PMCID: PMC7513535.
      Citations: 3     Fields:    Translation:HumansCells
    11. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629. PMID: 32239765.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    12. Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer J. 2019 11 28; 9(12):95. PMID: 31780660; PMCID: PMC6882812.
      Citations: 7     Fields:    Translation:HumansCells
    13. Vila IK, Park MK, Setijono SR, Yao Y, Kim H, Badin PM, Choi S, Narkar V, Choi SW, Chung J, Moro C, Song SJ, Song MS. A muscle-specific UBE2O/AMPKa2 axis promotes insulin resistance and metabolic syndrome in obesity. JCI Insight. 2019 07 11; 4(13). PMID: 31292296; PMCID: PMC6629239.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    14. Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491). PMID: 31068440.
      Citations: 61     Fields:    Translation:AnimalsCells
    15. Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, Chiu HH, Wu Y, Lee MG, Kalb RG, Hung MC, Pandolfi PP, Song SJ, Song MS, Billalabeitia EG. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun. 2019 02 07; 10(1):636. PMID: 30733438; PMCID: PMC6367354.
      Citations: 20     Fields:    Translation:AnimalsCells
    16. Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2019 03; 38(11):1802-1814. PMID: 30361685.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    17. Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J. 2018 03 20; 8(3):33. PMID: 29559616; PMCID: PMC5861115.
      Citations: 3     Fields:    Translation:HumansCells
    18. Vila IK, Yao Y, Kim G, Xia W, Kim H, Kim SJ, Park MK, Hwang JP, Hung MC, Song SJ, Song MS, Gonz?lez-Billalabeitia E. A UBE2O-AMPKa2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell. 2017 02 13; 31(2):208-224. PMID: 28162974; PMCID: PMC5463996.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    19. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
      Citations: 55     Fields:    Translation:HumansCells
    20. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013 Nov; 10(11):643-55. PMID: 24061039; PMCID: PMC3927982.
      Citations: 195     Fields:    Translation:HumansAnimals
    21. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA. BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal. 2013 Jan 08; 6(257):ra2. PMID: 23300339; PMCID: PMC3748614.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    22. Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, Sabapathy K, Menter DG, Abbruzzese JL, Reddy SAG. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res. 2009 May; 7(5):745-754. PMID: 19435822; PMCID: PMC4854281.
      Citations: 10     Fields:    Translation:HumansCells
    23. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005 Oct 15; 65(20):9164-8. PMID: 16230374.
      Citations: 22     Fields:    Translation:HumansCells
    24. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 2005 May 27; 331(1):295-302. PMID: 15845392.
      Citations: 32     Fields:    Translation:HumansCells
    25. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004 Nov 11; 23(53):8571-80. PMID: 15467756.
      Citations: 124     Fields:    Translation:HumansCells
    26. Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem. 2001 Apr 06; 276(14):11402-8. PMID: 11278366.
      Citations: 26     Fields:    Translation:HumansCells
    27. Erratum. Oncogene. 24:4320.
    YAO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (177)
    Explore
    _
    Co-Authors (48)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _